In A Record Year For US FDA Approvals, Pfizer Came Out On Top
FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders.
You may also be interested in...
Top 20 Pharma Ranks: As Some Move Up, Others Fall Down
Sanofi and Gilead moved down in the rankings of Scrip's top 100 pharmaceutical companies, based on 2017 pharma sales, while Johnson & Johnson, GSK and AbbVie moved up. Shire joined the top 20 just as it is about to be consumed by Takeda.
US FDA Blows Past Novel Approvals Record On Way To Unprecedented Year For New Drugs
Roche’s Xofluza brings novel approval count for CDER to 47, topping 2017's record – and FDA still has at least 14 novel agents under review with 2018 goal dates.
Servier Acquires Shire Oncology Business For $2.4bn
French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn